{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Restrict the search for
larotrectinib
to a specific field?
There is one exact (name or code) match for larotrectinib
Status:
US Approved Rx
(2018)
Source:
NDA210861
(2018)
Source URL:
First approved in 2018
Source:
NDA210861
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Targets:
Larotrectinib (previously known as ARRY-470 and LOXO-101) is a potent, oral and selective investigational new drug in clinical development for the treatment of patients with cancers that harbor abnormalities involving the tropomyosin receptor kinases (TRKs). Larotrectinib is in phase II clinical trials for the treatment patients with solid tumors, non-Hodgkin lymphoma and for the pediatric patients with advanced solid or primary CNS tumors.
Status:
US Approved Rx
(2018)
Source:
NDA210861
(2018)
Source URL:
First approved in 2018
Source:
NDA210861
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Targets:
Larotrectinib (previously known as ARRY-470 and LOXO-101) is a potent, oral and selective investigational new drug in clinical development for the treatment of patients with cancers that harbor abnormalities involving the tropomyosin receptor kinases (TRKs). Larotrectinib is in phase II clinical trials for the treatment patients with solid tumors, non-Hodgkin lymphoma and for the pediatric patients with advanced solid or primary CNS tumors.
Status:
Possibly Marketed Outside US
Source:
Octaplasma by Octapharma Pharmazeutika Produktionsges M B H [Canada]
Source URL:
First approved in 2013
Source:
BLA125416
Source URL:
Class:
MIXTURE
![Structure of 5-[(2R)-2-(2,5-Difluorophenyl)-1-pyrrolidinyl]-3-nitropyrazolo[1,5-a]pyrimidine](/img/af89d791-8fc6-4f45-8125-d9979d90acb9.svg?size=200&context=ukgxvqialh)
![Structure of 5-[(2R)-2-(2,5-Difluorophenyl)-1-pyrrolidinyl]pyrazolo[1,5-a]pyrimidin-3-amine](/img/d8f479e8-f004-4cf3-aa18-b0ec6077a222.svg?size=200&context=ukgxvqialh)
![Structure of (R)-N-(5-((S)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide](/img/40840524-3a81-41bf-9d13-ba2da8a55a5c.svg?size=200&context=ukgxvqialh)
